Company facts
- Headquarters
- Emeryville, California
- Most recent report
- 8-K, filed Sep 24, 2026
- Incorporated
- Delaware
- Filings on record
- 187 filings
- On EDGAR
- CIK 1994702
- Fiscal year ends
- December
- Filer status
- Emerging growth company
Financials 8 of 11
News 8 of 41
Prospectuses and Registrations 8 of 15
- 424B5 Prospectus supplement for an offering Apr 2, 2026
- S-8 Registration statement for an employee plan Mar 26, 2026
- S-3 Shelf registration statement Mar 26, 2026
- 424B5 Prospectus supplement for an offering Dec 18, 2025
- FWP Free writing prospectus Dec 17, 2025
- 424B5 Prospectus supplement for an offering Dec 15, 2025
- 424B5 Prospectus supplement for an offering Apr 15, 2025
- S-8 Registration statement for an employee plan Mar 27, 2025
Proxies 4
Ownership 8 of 86
- SCHEDULE 13G Large holder reported a passive stake Oct 19, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G Large holder reported a passive stake Jul 29, 2026
- 4 Insider reported a trade May 29, 2026
- 4 Insider reported a trade May 29, 2026
- 4 Insider reported a trade May 29, 2026
- 4 Insider reported a trade May 29, 2026
- 4 Insider reported a trade May 29, 2026
Other 8 of 30
- ARS Annual report sent to shareholders Apr 13, 2026
- EFFECT Notice that a registration became effective Apr 2, 2026
- CORRESP Reply to SEC staff Mar 31, 2026
- UPLOAD Comment letter from SEC staff Mar 30, 2026
- EFFECT Notice that a registration became effective Apr 15, 2025
- ARS Annual report sent to shareholders Apr 14, 2025
- CORRESP Reply to SEC staff Apr 11, 2025
- UPLOAD Comment letter from SEC staff Apr 1, 2025
Everything here comes from Kyverna Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.